Ascendis Pharma A/S Stock News

In this article we will check out the progression of hedge fund sentiment towards Ascendis Pharma A/S (NASDAQ:ASND) and determine whether it is a good investment right now. We at Insider Monkey like t

Travis Scott‘s Nike collaborations have always had one thing in common: they’re all pure reflections of the artist’s own personal style. And while at first not as overt or as well-defined, the r

Investors in Ascendis Pharma A/S (NASDAQ:ASND) had a good week, as its shares rose 5.0% to close at US$147 following...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (...

– On track for filing U.S. Biologics License Application for TransCon hGH in second quarter, and advancing Marketing Authorisation Application in Europe to third quarter  – –.

NEW YORK, NY / ACCESSWIRE / May 19, 2020 / Ascendis Pharma A/S (NASDAQ:ASND) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 19, 2020 at 4:30 PM E

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE:...

Biotech stocks had another up week, with the American Society of Gene & Stem Cell Therapy virtual conference presentations and the ASCO abstracts made available online ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ...

Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will appoint Jesper Høil

As the month of May kicked off, stocks got off to a rocky start. The market slumped in response to a first quarter profit miss from eCommerce giant Amazon (NASDAQ:AMZN) and its plan to put all second-

Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will hold a conference ca

In a report issued on April 27, Michelle Gilson from Canaccord Genuity maintained a Buy rating on BioMarin Pharmaceutical (BMRN), with a price target of

In a report issued on April 27, Michelle Gilson from Canaccord Genuity maintained a Buy rating on BioMarin Pharmaceutical ( BMRN – Research Report ), with a price target of $108.00 . The company’s

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on SLANG Worldwide (SLGWF), Stryker (SYK) and BioMarin